Challenges in Health Insurance Coverage for Rare Cancer Treatments

In 2015, Carol Player, initially believing she had a temporary eye irritation from perfume, was diagnosed with ocular melanoma. The condition led to the amputation of her right eye, with later developments revealing cancer spread to her liver. She was advised to pursue chemosaturation therapy, a treatment not provided by the National Health Service (NHS) but covered by certain private health insurers. Part of a clinical trial, the therapy demonstrated effectiveness, slowing tumor growth in 89% of cases. Despite holding comprehensive cancer coverage with Axa Health, Player's claim for the chemosaturation therapy was denied. Axa argued against covering the treatment, citing its limited use and insufficient clinical trials. Player has since initiated legal proceedings, claiming Axa applied an overly restrictive interpretation of policy terms. Her lawyer, Luke Harrison, encountered a similar denial but secured an out-of-court settlement for his rare cancer treatment. To cover her costly treatment, Player amassed £120,000 through savings and community support. Although she experienced remission following therapy, her cancer recurred in 2024, necessitating self-funding for additional rounds. While the National Institute for Health and Care Excellence (NICE) has deemed chemosaturation safe when conducted by specialists, it remains off the NHS's support list due to resource allocation concerns. Axa continues to withhold coverage, a stance mirrored by other patients like Lee Andrews and Sam Franklin, despite policy memberships promising potential life-extending treatments. The difficulty of switching health insurance policies post-diagnosis is evident, as most exclude pre-existing conditions, complicating access for individuals requiring ongoing care. These patient challenges have sparked legislative debates, with advocates like Scott Arthur pushing for improved frameworks and support for rare cancer treatments. The emerging Rare Cancers Bill seeks to motivate research and streamline drug approval processes. Axa, a prominent player in the UK's insurance market serving over 2.8 million clients, has faced significant customer complaints, particularly concerning cancer treatment denials. In response, Axa emphasizes its commitment to conforming with regulatory compliance requirements, maintaining that it rigorously evaluates treatment eligibility based on the latest clinical evidence and guidelines. The private health insurance sector remains crucial in the UK, highlighting the necessity for clear communication and robust policy frameworks to effectively support patients.